The Spartanburg Community Clinical Oncology Program (SCCOP) has the following specific aims: 1) provide adequate support for expanding the clinical research effort in our community; 2) involve primary care physicians early in the course of clinical treatment research and therefore speed the transfer of newly developed technology to the community reducing cancer mortality; 3) facilitate wider community participation in future cancer control preventive research activities; 4) serve as part of a broadly based nation wide resource for quality controlled distribution of increasing numbers of experimental anti-cancer agents. SCCOP will associate itself with the Piedmont Oncology Association of the Oncology Research Center (POA) of the Bowman Gray School of Medicine as our research base. The POA will provide access to POA protocols and protocols of CALGB, GOG, and NSABP. The data management proposal will: 1) insure an alertness to the available protocols to achieve a minimum registration of 50 patients per year (or 10% of those eligible); 2) maintain a daily patient log of all patients seen in the SCCOP indicating diagnosis, stage, eligibility for protocol, protocol accession or reason not accessed; 3) register and manage patients in accordance with the procedure of the POA and as outlined in the letters of agreement between the SCCOP and POA. The multidisciplinary team of the SCCOP will be assisted in these endeavors by a full time SCCOP Oncology Nurse/Protocol Data Coordinator, a full time SCCOP Secretary/Data Manager, and part time support for appropriate administrative and fiscal personnel to be funded by this consortium grant. The successful operation of the SCCOP is expected to improve the quality of cancer care in our community while simultaneously increasing the number of patients accessed to clinical trials and improving the quality of the associated data management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035119-03S1
Application #
3557525
Study Section
(SRC)
Project Start
1983-09-01
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Spartanburg Regional Medical Center
Department
Type
DUNS #
052072048
City
Spartanburg
State
SC
Country
United States
Zip Code
29303
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95

Showing the most recent 10 out of 202 publications